AWH Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

AWH Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,500	Closed	-$276K	–	46
2020 Q3	$276K	Buy	+11,500	New	+$282K	0.39%	37

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AWH Capital's RIGL Position: Q4 2020 in Review

AWH Capital sold out of Rigel Pharmaceuticals (RIGL) in Q4 2020, closing a stake of 11,500 shares — an estimated $276K sold.

AWH Capital first reported a position in RIGL in Q3 2020 and held it in 1 quarter. The position peaked at $276K in Q3 2020. 149 funds tracked by Wall St. Rank hold RIGL as of Q4 2020.

AWH Capital reported no remaining Rigel Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
AWH Capital sold 11,500 Rigel Pharmaceuticals shares in Q4 2020, an estimated $276K.
AWH Capital first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 1 quarter.
AWH Capital's Rigel Pharmaceuticals position peaked at $276K in Q3 2020.
149 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2020.

Based on AWH Capital's 13F filing for Q4 2020, filed 16 Feb 2021.